NEW YORK (GenomeWeb) – CareDx reported after the close of the market on Thursday that its third quarter revenues fell 2 percent mostly due to a 5 percent dip in revenues from its non-invasive heart transplant rejection test AlloMap.

For the three months ended Sept. 30, the firm reported total revenues of $12.2 million, down from $12.5 million in Q3 2016, but beating the average Wall Street estimate for revenues of $12.1 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.